描述

Intravenous Immunoglobulin (IVIG) is a therapy treatment for patients with antibody deficiencies. It is prepared from a pool of immunoglobulins (antibodies) from the plasma of thousands of healthy donors. Immunoglobulins are made by the immune system of healthy people for the purpose of fighting infections. 根据StrategyHelix, the intravenous immunoglobulin market in United States is expected to increase by US$ 2.5 亿期间 2022-2028, 复合年增长率为 6.4% 在预测期内.

该报告提供了该时期的最新市场规模数据 2018-2021 并预测到 2028 covering key market aspects like sales value for intravenous immunoglobulin. The United States intravenous immunoglobulin market is segmented on the basis of application, 和最终用户. Based on application, the intravenous immunoglobulin market in United States is categorized into chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, 其他的. The immunodeficiency diseases segment held the largest share of the United States intravenous immunoglobulin market in 2021 预计在预测期内将持有其份额. 基于最终用户, the intravenous immunoglobulin market in United States has been segmented into homecare, 医院 & 诊所.

The United States intravenous immunoglobulin market is highly competitive. Key companies profiled in the report include ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols S.A., 约翰逊 & 约翰逊, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited. Competitive landscape gives a description of the competitive nature of the intravenous immunoglobulin market in United States and a description of the leading companies. 确定了近年来塑造市场的关键金融交易.

该报告对于活跃在该行业的公司和组织来说是宝贵的资源. It provides a cohesive picture of the intravenous immunoglobulin market to help drive informed decision making for industry executives, 政策制定者, 学术的, 和分析师.

报告范围

应用: chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, 其他的
最终用户: homecare, 医院 & 诊所
考虑的年数: 本报告涵盖期间 2018 到 2028
提到的公司: ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols S.A., 约翰逊 & 约翰逊, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited

利益相关者的主要好处

– Get a comprehensive picture of the United States intravenous immunoglobulin market
– 根据当地数据确定区域战略和战略重点
– 精准定位增长领域和投资趋势

目录

部分 1. 介绍
– 研究范围
– 学习时段
– 地理范围
– 研究方法论
部分 2. Intravenous immunoglobulin market overview
部分 3. 按应用划分的市场细分
– Chronic inflammatory demyelinating polyneuropathy (CIDP)
– Chronic lymphocytic leukemia
– Congenital HIV/AIDS
– Guillain-barre syndrome (GBS)
– Hypogammaglobulinemia
– Immune thrombocytopenic purpura (ITP)
– Immunodeficiency diseases
– Kawasaki disease
– Multifocal motor neuropathy (MMN)
– Myasthenia gravis
– 其他的
部分 4. 按最终用户划分的市场细分
– Homecare
– 医院 & 诊所
部分 5. 重点企业
– ADMA Biologics Inc.
– Biotest AG
– CSL Limited
– Grifols, 南非.
– 约翰逊 & 约翰逊
– Kedrion Biopharma Inc. (Kedrion SpA)
– LFB S.A.
– Octapharma AG
– Takeda Pharmaceutical Company Limited
关于StrategyHelix
免责声明